MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

Exact Sciences has launched its long-awaited blood test designed to detect the early stages of multiple tumors, with a plan to sell it to consumers through a telehealth program in a bid to increase ...

A foundational guide for stage 2 prostate cancer clarifies staging implications, localized-disease management, and trade-offs among surgery, radiation, and quality-of-life outcomes to support informed ...

Fragmented subspecialty care and underbuilt survivorship pathways risk overwhelming primary care as the survivor population ...

Cancer will claim an estimated 618,000 lives in the U.S. in 2025, according to the American Cancer Society. Yet, despite advances in treatment, most of these deaths stem from cancers without guideline ...

Cancer is the second leading cause of death within the US. The sooner it is detected through screening, the sooner it can be ...